18:37 25/05/2017 Pfizer Inc.: FDA Advisory Committee Recommends Approval of Pfizer's Proposed ...
Pfizer Inc.: FDA Advisory Committee Recommends Approval of Pfizer's Proposed ...
The Wall Street Transcript - 32 minutes ago
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company's proposed epoetin alfa ...

13:22 25/05/2017 Target Price ($37.53) for Pfizer Inc. (PFE) now above Open ($32.12) for Wednesday
Target Price ($37.53) for Pfizer Inc. (PFE) now above Open ($32.12) for Wednesday
NY Stock News - 5 hours ago
Pfizer Inc. (PFE) has built up a compelling picture over the last few trading sessions and both traders and analysts are now starting to take a keen look at the stock.
Bridges Investment Counsel Inc. Sells 33920 Shares of Pfizer Inc. (PFE) - The Cerbat Gem
Hope For Cancer Patients After Pfizer Inc (NYSE:PFE) Strikes The Medivation ... - Journal Transcript

17:52 24/05/2017 This Is What The Chart For Pfizer Inc. (PFE) Is Showing Today
This Is What The Chart For Pfizer Inc. (PFE) Is Showing Today
NY Stock News - May 24, 2017
The technicals for Pfizer Inc. (PFE) has spoken via its technical chart and the message is loud and clear. Based on that message, this is the relevant information necessary to make sense of that current setup.

3:48 24/05/2017 Pfizer Vs. Merck: 4 Reasons One Is The Superior Choice
Pfizer Vs. Merck: 4 Reasons One Is The Superior Choice
Seeking Alpha - May 24, 2017
Merck, as one of the world's largest drug makers, is a staple of millions of high-yield portfolios. However, when you actually look deeper into the fundamentals of the company, it becomes clear that Merck is a far inferior choice to higher-yielding and ...

17:52 22/05/2017 3 Big Stock Charts for Monday: Bristol-Myers Squibb Co (BMY), Pfizer Inc. (PFE ...
3 Big Stock Charts for Monday: Bristol-Myers Squibb Co (BMY), Pfizer Inc. (PFE ...
Investorplace.com - May 22, 2017
Stocks are ready to continue last week's recovery as traders continue to look for opportunities to buy the short-term dip caused by the political headlines from last week.

19:22 16/05/2017 Pfizer: There Is No Upside Without M&A
Pfizer: There Is No Upside Without M&A
Seeking Alpha - May 16, 2017
Thus, in this article, I will focus on a quantitative valuation of the company without taking into account any potential M&A that Pfizer could announce in 2017/2018, which looks unpredictable, to assess if there is any upside in the company, as ...

16:00 14/05/2017 Here's Why the Best Is Yet to Come for Pfizer Inc.
Here's Why the Best Is Yet to Come for Pfizer Inc.
Motley Fool - May 14, 2017
The company's acquisitions have added more likely winners. Pfizer bought Anacor in 2016, picking up atopic dermatitis drug Eucrisa, which won FDA approval in December.

16:11 03/05/2017 Pfizer Dividend Remains Attractive After Q1 Earnings
Pfizer Dividend Remains Attractive After Q1 Earnings
Seeking Alpha - May 3, 2017
Although an earnings beat was accompanied by a top line miss, I don't foresee much downside in shares here. Sales fell to $12.78 billion due to an underperformance in some of the company's patent-protected drugs such as Xeljanz. However Ibrance has ...
Pfizer Must Learn to Live With Uncertainty - Bloomberg

21:22 02/05/2017 3 Reasons Pfizer, Inc. Investors Shouldn't Be Concerned About the Q1 Revenue Dip
3 Reasons Pfizer, Inc. Investors Shouldn't Be Concerned About the Q1 Revenue Dip
Motley Fool - May 2, 2017
Pfizer, Inc. (NYSE:PFE) reported its first-quarter results before the market opened on Tuesday. The big drugmaker's revenue of $12.8 billion reflected a 2% drop from the prior-year period.
Pfizer Revenue Falls as Drugs Lose Exclusivity -- Update - Fox Business
Pfizer beats - Business Insider

11:52 02/05/2017 Pfizer Inc. Q1 Income Advances 0%
Pfizer Inc. Q1 Income Advances 0%
Nasdaq - May 2, 2017
(RTTNews.com) - Pfizer Inc. ( PFE ) released a profit for its first quarter that increased from last year. The company said its bottom line rose to $4.19 billion, or $0.69 per share.